Trial · NCT04347720
Canadian National PDA Treatment Study
NCT04347720, Completed, IWK Health Centre
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Canadian National PDA Treatment Study. Trials, record NCT04347720. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04347720
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Canadian National PDA Treatment Study
- NCT number
- NCT04347720
- Status
- Completed
- Enrollment
- 1,663 participants, actual
- Lead sponsor
- IWK Health Centre
- Conditions
- Patent Ductus Arteriosus, Extreme Prematurity
- Interventions
- Indomethacin, Ibuprofen, Acetaminophen
- First posted
- 2020-04-15
- Last updated
- 2024-06-21
Source ClinicalTrials.gov
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Failure of primary pharmacotherapy | through hospital discharge (approximately 20 weeks postnatal age unless death occurs first) | Receipt of further medical and/or surgical/interventional treatment following an initial course of pharmacotherapy |
| Secondary | Receipt of 2nd course of pharmacotherapy | through hospital discharge (approximately 20 weeks postnatal age unless death occurs first) | |
| Secondary | Surgical/interventional PDA closure | through hospital discharge (approximately 20 weeks postnatal age unless death occurs first) | |
| Secondary | Chronic lung disease | birth through 36 weeks post menstrual age | Oxygen or respiratory support requirement at 36 weeks' postmenstrual age or at discharge |
| Secondary | Necrotizing enterocolitis | through hospital discharge (approximately 20 weeks postnatal age unless death occurs first) | Stage 2 or greater as per Bell's criteria |
| Secondary | Severe intraventricular hemorrhage | through hospital discharge (approximately 20 weeks postnatal age unless death occurs first) | Grade III-IV according to Papile Criteria |
| Secondary | Definite sepsis | through hospital discharge (approximately 20 weeks postnatal age unless death occurs first) | Clinical symptoms and signs of sepsis and a positive bacterial culture in a specimen obtained from normally sterile fluids or tissue obtained at postmortem |
| Secondary | Acute Kidney Injury | through hospital discharge (approximately 20 weeks postnatal age unless death occurs first) | Stage 1 or greater according to the Neonatal AKI KDIGO classification |
| Secondary | Post-treatment serum bilirubin | within 7 days of initiation of pharmacotherapy | |
| Secondary | Maximum serum AST and ALT (u/L) during treatment or within 1 week of treatment completion | within 7 days of completion of pharmacotherapy |
1 to 10 of 11Source ClinicalTrials.gov
See all 11 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 33952559 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04347720
GET https://conductscience.org/api/trials/v1/NCT04347720/registered